Hepatic Cell News

Hepatic Cell News is an online resource covering the top research on hepatocytes and liver diseases.

Nuclear Pirin Promotes HCC by Acting As a Key Inflammation-Facilitating Factor

April 10, 2026

[Gut] Scientists investigated the role of the oxidative stress sensor protein Pirin as a critical mediator of inflammation in hepatocellular carcinoma progression.

Selenoprotein P Deficiency Drives Hepatocellular Carcinoma Progression via Induction of Neutrophil Senescence and Immunosuppressive Microenvironment

April 10, 2026

[Gut] Researchers elucidated the role of Selenoprotein P-mediated selenium metabolism in driving the accumulation and immunosuppressive function of senescent-like neutrophils in HCC.

Posttranscriptional Reprogramming Controls MASLD Progression through Chronic ER Stress Adaptation

April 10, 2026

[Science Advances] Using an integrative approach combining transcriptomics, ribosome profiling, cytoplasmic polyadenylation analysis, and cis-regulatory mapping, investigators defined the posttranscriptional landscape induced by chronic high-fat diet exposure.

Overexpression of ONECUT1 Suppresses Hepatoblastoma Progression via Modulating Tumor Cell Growth and Tumor Microenvironment

April 10, 2026

[Cell & Bioscience] Researchers generated doxycycline-inducible expression systems to upregulate One Cut Homeobox 1 (ONECUT1) in hepatoblastoma cells in culture and in mouse models.

Suppression of LRRC41-Mediated Oncogenicity in Hepatocellular Carcinoma via USP7-Targeted Small Molecule Inhibitors

April 10, 2026

[British Journal of Cancer] The authors explored the molecular mechanism by which LRRC41 promotes HCC malignancy and investigated the therapeutic potential of inhibiting its mediated signalling pathway.

SETDB2 Induces Abnormal SHP-1 Splicing and Promotes Immunosuppression in Hepatocellular Carcinoma

April 10, 2026

[Oncogene] Scientists constructed a patient-derived xenograft model of HCC to compare and analyze the tumor tissues of the immunotherapy responder group and the non-responder group.

Hepatocyte-Derived IL-25 Promotes Macrophage Extracellular Trap Formation and Drives Liver Fibrosis Progression

April 10, 2026

[Inflammation] To elucidate the specific role of interleukin-25 (IL-25), hepatocyte-specific IL-25 conditional knockout mice were generated using CRISPR/Cas9 technology and subjected to the liver fibrosis model.

Organoid Models in Viral Hepatitis, Primary Liver Cancer, and Non-Alcoholic Fatty Liver Disease: Advances, and Challenges

April 10, 2026

[Hepatobiliary & Pancreatic Diseases International] Scientists introducedthe application of organoids in liver diseases, and focused on viral hepatitis, primary liver cancer, and non-alcoholic fatty liver disease due to their high prevalence and the maturity of organoids in these areas.

CatalYm Doses First Patient in Phase IIb Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma

April 10, 2026

[CatalYm] CatalYm announced that the first patient has been dosed in the GDFATHER-HCC-01 trial. The Phase IIb trial targets patients who have progressed following 1L treatment with an anti-PD-(L)1-based therapy.

Sex-Specific KDM6A-HNF4A-CREBH Network Controls Lipoprotein Cholesterol Metabolism and Atherosclerosis via Epigenetic Reprograming of Hepatocytes

March 26, 2026

[Nature Communications] Researchers showed that the X-linked histone demethylase 6 A (KDM6A) is essential for maintaining healthy cholesterol metabolism in the liver.

Targeted Inhibition of Nrf2 Potentiates Antitumor Immunity and Enhances the Efficacy of Immunotherapy in Hepatocellular Carcinoma

March 26, 2026

[Journal for Immunotherapy of Cancer] Investigators offered a novel strategy to enhance HCC immunotherapy by blocking nuclear factor erythroid 2-related factor 2 (Nrf2), which has the potential to address the low response rates observed with current HCC immunotherapies.

Targeting STE20-Type Kinase MST3 Improves Metabolic Dysfunction-Associated Steatohepatitis Without Affecting Hepatocellular Carcinoma Development in Mice

March 26, 2026

[BMC Medicine] Scientists investigated whether pharmacologic inhibition of MST3 could attenuate the initiation and progression of metabolic dysfunction-associated steatohepatitis-associated HCC in vivo.

The publications featured in Hepatic Cell News are expertly selected by our in-house editorial team from high impact, peer-reviewed academic journals. We cover areas including the culturing and characterization of hepatocytes, liver stem cells, and the pathogenesis of conditions such as liver cirrhosis and hepatocellular carcinoma. Additionally, we provide the latest updates on broader news, upcoming events, and job postings to keep the global liver research community connected!